生理盐水与乳酸林格氏液用于急性胰腺炎液体复苏的开放标签多中心随机对照试验:WATERLAND试验研究方案
WATERLAND试验为国际多中心、开放标签、平行组、随机对照优效性试验,计划将急性胰腺炎患者按1:1随机分配接受乳酸林格氏液或生理盐水液体复苏至少48小时,主要结局为修订版亚特兰大分类的中重度或重度急性胰腺炎,总样本量792例(每组396例,考虑10%失访),旨在评估乳酸林格氏液对比生理盐水的疗效与安全性。
要点
- WATERLAND试验比较乳酸林格氏液与生理盐水用于急性胰腺炎液体复苏的疗效与安全性。
- 主要结局为修订版亚特兰大分类定义的中重度或重度急性胰腺炎。
- 计划总样本量792例,每组396例,按1:1随机分配,液体复苏至少48小时。
核心结论
- WATERLAND试验旨在研究乳酸林格氏液对比生理盐水用于急性胰腺炎患者液体复苏的疗效与安全性。
- 若某一治疗组显示出更好的胰腺炎演变,将对该常见疾病的管理产生重要影响。
研究设计与样本
- WATERLAND试验为国际多中心、开放标签、平行组、随机对照优效性试验。
- 患者按1:1比例随机分配接受乳酸林格氏液或生理盐水为基础的液体复苏至少48小时。
- 计划总样本量720例(乳酸林格氏液组360例,生理盐水组360例),预计10%失访,故每组396例,总样本量792例。
- 采用双侧Z检验,合并方差,显著性水平设为0.05。
主要发现
- 假设乳酸林格氏液组中重度或重度急性胰腺炎发生率为17%,720例样本可达到90%把握度检测组间比例差异10%。
关键数值与推荐
- 主要结局为修订版亚特兰大分类定义的中重度或重度急性胰腺炎。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some evidence suggests that fluid resuscitation with lactated Ringer's solution (LR) may have an anti-inflammatory effect on acute pancreatitis (AP) when compared to normal saline (NS) and may be associated with a decrease in severity, but existing single-center randomized controlled trials showed conflicting results. The WATERLAND trial aims to investigate the efficacy and safety of fluid resuscitation using LR compared to NS in patients with AP. METHODS: The WATERLAND trial is an international multicenter, open-label, parallel-group, randomized, controlled, superiority trial. Patients will be randomly assigned in a 1:1 ratio to receive LR versus NS-based fluid resuscitation for at least 48 h. The primary outcome will be moderately severe or severe AP, according to the revision of the Atlanta classification. The secondary objectives of the WATERLAND trial are to determine the effect of LR versus NS fluid resuscitation on several efficacy and safety outcomes in patients with AP. A total sample of 720 patients, 360 in the LR group and 360 in the NS group, will achieve 90% power to detect a difference between the group proportions of 10%, assuming that the frequency of moderately severe or severe AP in the LR group will be 17%. A loss to follow-up of 10% of patients is expected, so the total sample size will be 396 patients in each treatment arm (792 patients overall). The test statistic used is the two-sided Z test with pooled variance set at a 0.05 significance level. DISCUSSION: The WATERLAND study aims to improve the early management of AP. Fluid resuscitation is an inexpensive treatment available in any hospital center worldwide. If a better evolution of pancreatitis is demonstrated in one of the treatment arms, it would have important repercussions in the management of this frequent disease. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05781243. Registration date on January 4, 2023. EudraCT number 2023-000010-18, first posted March 23, 2023.
引用
- Guilabert L, Cárdenas-Jaén K, Vaillo-Rocamora A, et al. Normal saline versus lactated Ringer's solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: the WATERLAND trial study protocol. Trials. 2024. PMID: 39434191. doi:10.1186/s13063-024-08539-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。